Matters


Invokana clinical trial shows drug doubles risk of amputation

June 22, 2017 - Jansen reported Invokana reduced the risk of cardiovascular complications in diabetic patients, but it also doubled the number of amputations for patients taking Invokana compared to the... Read More


J&J and Jansen Pharmaceuticals look to expand uses for Invokana despite growing lawsuits

February 16, 2017 - Researchers have tracked additional data about patients’ renal outcomes as a result of Invokana's link to a number of serious renal-impairing side effects including diabetic ketoacidosis... Read More


Beasley Allen lawyer Danielle Mason selected to help lead Invokana MDL

January 25, 2017 - Danielle Ward Mason, the firm’s leading Invokana attorney, has been appointed to serve on the Plaintiffs’ Steering Committee for Invokana multidistrict litigation. Read More


Invokana and Ketoacidosis

November 1, 2016 - Invokana, which contains the drug ingredient canagliflozin, was approved by the Food and Drug Administration (FDA) in March 2012. It is classified as an SGLT2 inhibitor, which works by... Read More


Diabetes drug Invokana linked to ketoacidosis

September 30, 2016 - Invokana, which contains the drug ingredient canagliflozin, was approved by the Food and Drug Administration (FDA) in March 2012. Read More


Invokana and its class of Type 2 diabetes drugs linked to serious health risk ketoacidosis

November 3, 2015 - A new class of Type 2 diabetes treatments, which includes the popular drug Invokana, has been linked to a serious condition of too much acid in the blood, known as ketoacidosis. Read More


back to top